期刊
BREAST CANCER RESEARCH AND TREATMENT
卷 186, 期 2, 页码 305-316出版社
SPRINGER
DOI: 10.1007/s10549-020-06054-x
关键词
Plasminogen activator inhibitor-1 (PAI-1); Extra virgin olive oil (EVOO); Oleuropein; ER; PR-responsive human cancer; MDA-MB-231; MCF-7
类别
资金
- European Union (European Social Fund-ESF) through the Operational Program Human Resources Development, Education and Lifelong Learning [2019-050-0503-18066]
Elevated levels of PAI-1 are inversely correlated with ER and PR expressions in estrogen/progesterone-responsive human malignancies. In silico molecular docking analysis identified oleuropein as a potent PAI-1-binding molecule with increased affinity compared to other olive oil constituents. Oleuropein acts as a natural PAI-1 inhibitor by destabilizing PAI-1 levels selectively in ER-/PR- breast cancer cells, leading to downstream caspase activation and cell growth inhibition.
Purpose Elevated expression of PAI-1 has been widely linked with adverse outcomes in a variety of human cancers, such as breast, gastric and ovarian cancers, rendering PAI-1 a prognostic biomarker. As a result, several chemical inhibitors are currently being developed against PAI-1; however, the clinical setting where they might confer survival benefits has not yet been elucidated. Methods RNA sequencing data analysis from the TCGA/GTEx cancer portals (n = 3607 samples). In silico molecular docking analyses to predict functional macromolecule interactions. ER-/PR- (MDA-MB-231) and ER+/PR+ (MCF-7) breast cancer cell lines implemented to assess the effect of oleuropein as a natural inhibitor of PAI-1-mediated oncogenic proliferation. Results We show that high PAI-1 levels inversely correlate with ER and PR expressions in a wide panel of estrogen/progesterone-responsive human malignancies. By implementing an in silico molecular docking analysis, we identify oleuropein, a phenolic component of olive oil, as a potent PAI-1-binding molecule displaying increased affinity compared to the other olive oil constituents. We demonstrate that EVOO or oleuropein treatment alone may act as a natural PAI-1 inhibitor by incrementally destabilising PAI-1 levels selectively in ER-/PR- breast cancer cells, accompanied by downstream caspase activation and cell growth inhibition. In contrast, ER+/PR+ breast cancer cells, where PAI-1 expression is absent or low, do not adequately respond to treatment. Conclusions Our study demonstrates an inverse correlation between PAI-1 and ESR1/PGR levels, as well as overall patient survival in estrogen/progesterone-responsive human tumours. With a focus on breast cancer, our data identify oleuropein as a natural PAI-1 inhibitor and suggest that oleuropein-mediated PAI-1 destabilisation may confer clinical benefit only in ER-/PR- tumours.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据